Apeloa Pharmaceutical Co

Apeloa Pharmaceutical Co Dividend Yield

The Dividend Yield of Apeloa Pharmaceutical Co (000739.SZ) as of Oct 24, 2026 is 3.87 %. In the previous year, Dividend Yield was 1.74 % — a change of 122.27% (higher).

Dividend Yield

3.87 %

YoY

122.27%

Last updated:

Dividend Yield of Apeloa Pharmaceutical Co is 2025 3.87 % . Dividend Yield of Apeloa Pharmaceutical Co was 2024 1.74 % . It decreases by 122.27% higher compared to the previous year.

The Apeloa Pharmaceutical Co Dividend Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend Yield
Date
Dividend Yield
Jan 1, 2018
0.36 CNY
Jan 1, 2019
0.60 CNY
Jan 1, 2020
0.91 CNY
Jan 1, 2021
1.33 CNY
Jan 1, 2022
1.56 CNY
Jan 1, 2023
1.63 CNY
Jan 1, 2024
1.74 CNY
Jan 1, 2025
3.87 CNY
The Apeloa Pharmaceutical Co Dividend Yield history
YEARDividend YieldYoY
3.87 %+122.27%
1.74 %+6.70%
1.63 %+4.21%
1.56 %+17.28%
1.33 %+47.27%
0.91 %+50.00%
0.60 %+69.23%
0.36 %-5.80%
0.38 %+25.45%
0.30 %-35.29%
0.47 %+1,005.04%
0.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apeloa Pharmaceutical Co Stock analysis

What does Apeloa Pharmaceutical Co do? Apeloa Pharmaceutical Co., Ltd. generates revenue through the research, development, and production of active pharmaceutical ingredient (API) intermediates, contract development and production services (CDMO), and preparations. The company’s main products include bulk drugs, intermediates, chemical preparations, and Chinese traditional medicine preparations such as ubenimex capsules, cefixime, and amantadine. These products are sold to both domestic and overseas markets, with the company distributing its offerings across these segments. The firm’s business model focuses on serving pharmaceutical manufacturers and healthcare providers through its comprehensive range of API intermediates and finished preparations. The company’s revenue streams are derived from the sale of bulk drugs, intermediates, and chemical preparations, alongside its Chinese traditional medicine preparations like ubenimex capsules and cefixime. These products are targeted at pharmaceutical manufacturers seeking API intermediates and finished drug formulations. Apeloa Pharmaceutical serves both domestic and international clients, with its products distributed in both markets. The company’s CDMO services further support clients in the development and production of pharmaceutical products. Apeloa Pharmaceutical’s core business involves the production and sale of API intermediates, bulk drugs, and various preparations, including traditional Chinese medicine products. The company’s main customers are pharmaceutical manufacturers and healthcare providers who require intermediates for drug manufacturing and finished preparations for market distribution. Its domestic and overseas market presence ensures a diversified revenue base, with products like ubenimex capsules and amantadine contributing to its product portfolio. Apeloa Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Apeloa Pharmaceutical Co stock

Dividend Yield of Apeloa Pharmaceutical Co is 3.87 % in 2025.

Dividend Yield of Apeloa Pharmaceutical Co changed from 1.74 % to 3.87 %, representing a 122.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Dividend Yield Apeloa Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Dividend yield measures the annual dividend payment relative to the stock price. It shows the return an investor receives from dividends alone.

Dividend Yield's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Yield's Apeloa Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Apeloa Pharmaceutical Co

All Key Metrics — Apeloa Pharmaceutical Co